Interview: Novartis's Big Hopes For Beovu
Drug Gets EU Okay For Wet AMD
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
You may also be interested in...
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
Despite the impact from COVID-19, Novartis performed strongly in the second quarter "demonstrating resilience and agility of our associates and operations," according to CEO Vas Narasimhan. However, there is cause for concern at its ophthalmogy business and those problems are certainly not all down to coronavirus.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.